Skip to main content

Table 2 Study characteristics

From: Opinions on registering trial details: a survey of academic researchers

Variables

Total

E-mail available*

E-mail not available

p**

Responders

Non-responders

p

Recruiting status of study

1500

1299

201

0.15

282

1017

0.68

   Recruiting

1375 (91.7)

1196 (92.1)

179 (89.0)

 

258 (91.5)

938 (92.23)

 

   Not yet

125 (8.3)

103 (7.9)

125 (8.3)

 

24 (8.5)

79 (7.8)

 

Type of sponsor

   

<0.001

  

<0.001

   NIH

288 (19.2)

207 (15.9)

81 (40.3)

 

21 (7.4)

186 (18.3)

 

   Other

1212 (80.8)

1092 (84.1)

120 (59.7)

 

261 (92.5)

831 (81.7)

 

Study condition according to ICD 10

   

<0.001

  

0.03

   Infections

69 (4.6)

64 (4.9)

5 (2.5)

 

22 (7.8)

42 (4.1)

 

   Oncology

608 (40.5)

474 (36.5)

134 (66.7)

 

73 (25.9)

401 (39.4)

 

   Haematology

23 (1.5)

19 (1.5)

4 (2.0)

 

3 (1.1)

16 (1.6)

 

   Endocrinologic diseases

85 (5.7)

79 (6.1)

6 (3.0)

 

21 (7.4)

58 (5.7)

 

   Psychiatric diseases

119 (7.9)

109 (8.4)

10 (4.9)

 

28 (9.9)

81 (8.0)

 

   Neurologic diseases

62 (4.1)

58 (4.6)

4 (2.0)

 

14 (5.0)

44 (4.3)

 

   Eye

12 (0.8)

2 (1.0)

10 (0.8)

 

2 (0.7)

8 (0.8)

 

   Ear

2 (0.1)

2 (0.1)

0 (0.0)

 

1 (0.3)

1 (0.1)

 

   Cardiovascular diseases

123 (8.2)

118 (9.1)

5 (2.5)

 

30 (10.6)

88 (8.6)

 

   Lung diseases

59 (3.9)

53 (4.1)

6 (3.0)

 

10 (3.5)

43 (4.2)

 

   Digestive diseases

43 (3.3)

4 (2.0)

47 (3.1)

 

15 (5.2)

28 (2.7)

 

   Skin

19 (1.3)

18 (1.4)

1 (0.5)

 

3 (1.1)

15 (1.5)

 

   Musculoskeletal disorders

51 (3.4)

48 (3.7)

3 (1.5)

 

12 (4.3)

36 (3.5)

 

   Urology

76 (5.1)

72 (5.5)

4 (2.0)

 

20 (7.1)

52 (5.1)

 

   Pregnancy

26 (1.7)

23 (1.8)

3 (1.5)

 

5 (1.8)

18 (1.8)

 

   Perinatal disorders

10 (0.7)

10 (0.8)

0 (0.0)

 

3 (1.1)

7 (0.7)

 

   Labour

2 (0.1)

2 (0.1)

0 (0.0)

 

1 (0.3)

1 (0.1)

 

   Trauma

39 (2.6)

35 (2.7)

4 (2.0)

 

6 (2.1)

29 (2.8)

 

   Extern

1 (0.1)

1 (0.1)

0 (0.0)

 

1 (0.3)

0 (0.0)

 

   Other

67 (4.5)

61 (4.7)

6 (3.0)

 

12 (4.3)

49 (4.8)

 

Study intervention

   

<0.001

  

0.10

   Drug

895 (59.7)

741 (57.0)

154 (76.6)

 

143 (50.7)

598 (58.8)

 

   Procedure

231 (15.4)

211 (16.2)

20 (9.9)

 

55 (19.5)

156 (15.3)

 

   Behaviour

112 (7.5)

107 (8.2)

5 (2.5)

 

32 (11.3)

75 (7.4)

 

   Device

64 (4.3)

62 (4.8)

2 (1.0)

 

14 (5.0)

48 (4.7)

 

   Vaccine

17 (1.1)

12 (0.9)

5 (2.5)

 

3 (1.1)

9 (0.9)

 

   Gene therapy

5 (0.3)

4 (0.3)

1 (0.5)

 

0 (0.0)

4 (0.4)

 

   Other/not applicable

176 (11.7)

162 (12.5)

14 (7.0)

 

35 (12.4)

127 (12.5)

 

Study phase

   

<0.001

  

<0.01

   Phase I

137 (9.1)

113 (8.7)

24 (11.9)

 

19 (6.7)

94 (9.2)

 

   Phase II

357 (23.8)

281 (21.6)

76 (37.8)

 

45 (16.0)

236 (23.2)

 

   Phase III

230 (15.3)

206 (15.9)

24 (11.9)

 

51 (8.1)

155 (15.2)

 

   Phase IV

177 (11.8)

168 (12.9)

9 (4.5)

 

48 (17.0)

120 (11.8)

 

   Phase I/II

72 (4.8)

56 (4.3)

16 (8.0)

 

6 (2.1)

50 (4.9)

 

   Phase II/III

43 (2.9)

35 (2.7)

8 (4.0)

 

6 (2.1)

29 (2.8)

 

   Not applicable

484 (32.3)

440 (33.9)

44 (21.9)

 

107 (37.9)

333 (32.7)

 
  1. * E-mail address of principal investigator
  2. ** Chi-squared test
  3. Categories with less than six counts overall were added to category "Other" or "Other/not applicable" for the chi-square test.